These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 22429586)
1. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. Papp K; Menter A; Poulin Y; Gu Y; Sasso EH J Eur Acad Dermatol Venereol; 2013 May; 27(5):634-42. PubMed ID: 22429586 [TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. Gordon K; Papp K; Poulin Y; Gu Y; Rozzo S; Sasso EH J Am Acad Dermatol; 2012 Feb; 66(2):241-51. PubMed ID: 21752491 [TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Leonardi C; Sobell JM; Crowley JJ; Mrowietz U; Bao Y; Mulani PM; Gu Y; Okun MM Br J Dermatol; 2012 Sep; 167(3):658-67. PubMed ID: 22564148 [TBL] [Abstract][Full Text] [Related]
4. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Papp K; Crowley J; Ortonne JP; Leu J; Okun M; Gupta SR; Gu Y; Langley RG Br J Dermatol; 2011 Feb; 164(2):434-41. PubMed ID: 21083543 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study. Papp K; Ho V; Teixeira HD; Guerette B; Chen K; Lynde C J Eur Acad Dermatol Venereol; 2012 Aug; 26(8):1007-13. PubMed ID: 22023702 [TBL] [Abstract][Full Text] [Related]
7. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798 [TBL] [Abstract][Full Text] [Related]
8. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Reich K; Ortonne JP; Gottlieb AB; Terpstra IJ; Coteur G; Tasset C; Mease P Br J Dermatol; 2012 Jul; 167(1):180-90. PubMed ID: 22413944 [TBL] [Abstract][Full Text] [Related]
9. Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption. Gordon KB; Gottlieb AB; Langely RG; van de Kerkhof P; Belasco KT; Sundaram M; Okun M; Serra L J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):767-76. PubMed ID: 25284275 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. Menter A; Gordon KB; Leonardi CL; Gu Y; Goldblum OM J Am Acad Dermatol; 2010 Sep; 63(3):448-56. PubMed ID: 20605254 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360 [TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258 [TBL] [Abstract][Full Text] [Related]
13. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients. van Lümig PP; van de Kerkhof PC; Boezeman JB; Driessen RJ; de Jong EM J Eur Acad Dermatol Venereol; 2013 May; 27(5):593-600. PubMed ID: 22416818 [TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. Kimball AB; Papp KA; Wasfi Y; Chan D; Bissonnette R; Sofen H; Yeilding N; Li S; Szapary P; Gordon KB; J Eur Acad Dermatol Venereol; 2013 Dec; 27(12):1535-45. PubMed ID: 23279003 [TBL] [Abstract][Full Text] [Related]
15. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis. Ryan C; Kirby B; Collins P; Rogers S Clin Exp Dermatol; 2009 Oct; 34(7):784-8. PubMed ID: 19438535 [TBL] [Abstract][Full Text] [Related]
16. Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis. Gniadecki R; Leonardi CL; Gordon KB; Gu Y; Geng Z; Nader A; Teixeira HD J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1297-1304. PubMed ID: 29524255 [TBL] [Abstract][Full Text] [Related]
17. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Thaçi D; Ortonne JP; Chimenti S; Ghislain PD; Arenberger P; Kragballe K; Saurat JH; Khemis A; Sprøgel P; Esslinger HU; Unnebrink K; Kupper H Br J Dermatol; 2010 Aug; 163(2):402-11. PubMed ID: 20377585 [TBL] [Abstract][Full Text] [Related]
18. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558 [TBL] [Abstract][Full Text] [Related]
19. Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis. Navarini AA; Poulin Y; Menter A; Gu Y; Teixeira HD J Drugs Dermatol; 2014 May; 13(5):554-62. PubMed ID: 24809878 [TBL] [Abstract][Full Text] [Related]
20. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital. Noda S; Mizuno K; Adachi M J Dermatol; 2012 Mar; 39(3):265-8. PubMed ID: 22126280 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]